Ciudadela del Norte (C5) shows a medium level of total risk resulting from a medium level of physical risk and a medium high aggravation.
Palogrande (C8) presents a medium level of total risk resulting from a medium level of physical risk and a medium low aggravation.
Estación (C4) presents a medium level of total risk obtained from a medium high level of physical risk and a medium aggravation level.
Only 1 CA carrier and 0 of their matching controls lived in areas with medium densities of total farrowing swine.
Subjects in the medium tertile of total CA distribution experienced an RR of 1.36 (95% CI = 1.04 1.81, deaths = 136) and those in the high tertile an RR of 1.35 (95% CI = 1.03 1.80, deaths = 154).
The effect estimates for relationships between medium densities of total swine and farrowing swine and MRSA carriage were positive but imprecise (OR: 4.90; 95% CI: 0.57-42.16 and OR: 2.40, 95% CI: 0.81-7.09).
Compared to controls, HA carriers had higher odds of living in areas with medium densities of total (OR: 2.89, 95% CI: 0.30-28.26) and farrowing swine (OR: 2.45, 95% CI: 0.43-13.89), but similar odds of living in areas with medium densities of non-farrowing swine (OR: 0.97, 95% CI: 0.13-7.44).
Total microbial quantity score had a significant inverted-U-shaped association with asthma ever: the highest risk for asthma ever was found with the medium level of total microbial quantity score and the lowest risk with the highest quantity score (Fig. 2, Table 3).
Cells of the single deletion mutants lro1Δ and dga1Δ, and the double deletion mutant lro1Δdga1Δ were grown to the stationary phase either on glucose or oleic acid containing medium, lipids of total cells extracted and analyzed for the neutral lipid composition (see Materials and methods).
To count synaptic contacts, 7-day-old wt, podxl and wt primary cultures incubated with conditioned medium containing PC ectodomain (30 50 µl conditioned medium in 450 µl of total medium) or control medium (rabbit Fc) were fixed and labeled with the MAP-2 and Synapsin I and II antibodies.
